An intense hearing on Tuesday, expert testimony, and strategic debate on the validity of EP 2 493 466 (Cabazitaxel / Prednisone) in the first huge innovator v generics battle before the Unified Patent Court – a written decision is expected on 12 December 2025.

We at BONABRY had the privilege to represent STADA Group (together with Hamm & Wittkopp Patentanwälte) — side by side with excellent colleagues from df-mp/PENTARC (Elisabeth Greiner, Simon Geiger, Dr. Anja Lunze, LL.M., Aurel-Damian Roscher) for Zentiva, Maiwald Intellectual Property (Andreas Ledl, Dr. Sandra Unterseer, Dr. Christian Meyer, Tobias Matschke) for Dr. Reddy's Laboratories, and for a large part of the journey, Taylor Wessing for Accord Healthcare (Jules Fabre, Marina JONON, Louise Millot, Clémence de Marassé Enouf).

Grateful for the collaboration and team spirit — and especially for the trust placed in us by STADA. Proud of our own team effort: Alexander Wittkopp (Hamm & Wittkopp Patentanwälte), Konstantin Schallmoser, Yasmine Azzaoui, and Daniel Hoppe (Bonabry).